title: 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
abstract: The modulating effects of serotonin on dopamine neurotransmission are not well understood, particularly in acute psychotic states. Positron emission tomography was used to examine the effect of psilocybin on the in vivo binding of [11C]raclopride to D2-dopamine receptors in the striatum in healthy volunteers after placebo and a psychotomimetic dose of psilocybin (n = 7). Psilocybin is a potent indoleamine hallucinogen and a mixed 5-HT2A and 5-HT1A receptor agonist. Psilocybin administration (0.25 mg/kg p.o.) produced changes in mood, disturbances in thinking, illusions, elementary and complex visual hallucinations and impaired ego-functioning. Psilocybin significantly decreased [11C]raclopride receptor binding potential (BP) bilaterally in the caudate nucleus (19%) and putamen (20%) consistent with an increase in endogenous dopamine. Changes in [11C]raclopride BP in the ventral striatum correlated with depersonalization associated with euphoria. Together with previous reports of 5-HT receptor involvement in striatal dopamine release, it is concluded that stimulation of both 5-HT2A and 5-HT1A receptors may be important for the modulation of striatal dopamine release in acute psychoses. The present results indirectly support the hypothesis of a serotonin-dopamine dysbalance in schizophrenia and suggest that psilocybin is a valuable tool in the analysis of serotonin-dopamine interactions in acute psychotic states.
authors: Research Department, Psychiatric University Hospital Zürich, Switzerland.
authors: F X
authors: FX
authors: Vollenweider
authors: P
authors: P
authors: Vontobel
authors: D
authors: D
authors: Hell
authors: K L
authors: KL
authors: Leenders
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000493:pharmacokinetics*; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000493:pharmacokinetics*; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011562:Psilocybin / Q000494:pharmacology*; D011594:Psychometrics; D011605:Psychoses, Substance-Induced / Q000378:metabolism* / Q000523:psychology; D020891:Raclopride; D012457:Salicylamides / Q000493:pharmacokinetics*; D012701:Serotonin / Q000502:physiology*; D014055:Tomography, Emission-Computed
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D006213:Hallucinogens; D012457:Salicylamides; D011562:Psilocybin; D012701:Serotonin; D020891:Raclopride; D004298:Dopamine